Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03412773 · ClinicalTrials.gov registry record · Phase 3

A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

A Phase 3 study of Hepatocellular Carcinoma (HCC), sponsored by BeiGene.

Completed
Registry status
Phase 3
Development phase
684
Enrollment target
20
Study locations

NCT03412773 is a Phase 3 study of Hepatocellular Carcinoma (HCC) that has completed, run by BeiGene. The registered enrollment target is 684 participants, above the 306-participant average among 15 other Hepatocellular Carcinoma (HCC) trials with a reported enrollment target (124% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03412773, a Phase 3 study of Hepatocellular Carcinoma (HCC), has completed, sponsored by BeiGene.

COMPLETED
Registry status
Phase 3
Development phase
684 participants
Enrollment target
20
Study locations

Study Summary

This Phase 3 study was a global, multicenter trial that randomly assigned participants to either tislelizumab or sorafenib as a first-line treatment for adults with advanced liver cancer (hepatocellular carcinoma) that could not be surgically removed. Before enrolling Japanese participants in the main Phase 3 study, a preliminary assessment of safety and tolerability (the Safety Run-In Sub-study) was conducted in Japan.

Conditions Studied

Hepatocellular Carcinoma (HCC)

Interventions

  • DRUG Tislelizumab
  • DRUG Sorafenib

Study Locations (20)

Beijing Municipality

  • Cancer Hospital Chinese Academy of Medical Sciences - Beijing
  • Military Hospital of China - Beijing
  • Beijing Youan Hospital, Capital Medical University - Beijing
  • Beijing Cancer Hospital - Beijing
  • Peking Union Medical College Hospital - Beijing
  • Chinese Pla General Hospital - Beijing

Anhui

  • The First Affiliated Hospital of Bengbu Medical College - Bengbu
  • Anhui Provincial Hospital - Hefei
  • The First Affiliated Hospital of Anhui Medical University - Hefei
  • The Second Hospital of Anhui Medical University - Hefei

California

  • Providence Medical Foundation - Fullerton
  • UCLA Hematologyoncology - Los Angeles
  • Chao Family Comprehensive Cancer Center - Orange

Massachusetts

  • Massachusetts General Hospital - Boston

New Jersey

  • Umdnj Njms - Newark

New York

  • Rj Zuckerberg Cancer Center - Lake Success

Ohio

  • Xcancerdayton Physician Network - Dayton

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 684 participants
Start Date 2017-12-18
Est. Completion 2023-12-14
Phase Phase 3

Sponsor

BeiGene

65 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03412773

The ClinicalTrials.gov registry entry for NCT03412773 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 684 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 306-participant average among 15 other Hepatocellular Carcinoma (HCC) trials with a reported enrollment target (124% higher). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatocellular Carcinoma (HCC) appearing as the primary indexed condition, and to 2 interventions - of which Tislelizumab is the first listed.

NCT03412773 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Beijing Municipality, Anhui, California.

Frequently Asked Questions

What is clinical trial NCT03412773 about?

NCT03412773 is a clinical study titled "A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)". This Phase 3 study was a global, multicenter trial that randomly assigned participants to either tislelizumab or sorafenib as a first-line treatment for adults with advanced liver cancer (hepatocellular carcinoma) that could not be surgically removed. Before enrolling Japanese participants in the ma...

What is the current status of trial NCT03412773?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 684 participants. The study started on 2017-12-18. Estimated completion is 2023-12-14.

What conditions does trial NCT03412773 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma (HCC).

What interventions are being tested in trial NCT03412773?

The interventions under investigation include: Tislelizumab (DRUG), Sorafenib (DRUG).

Who is sponsoring clinical trial NCT03412773?

This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03412773 being conducted?

This trial has 20 study locations across California, Massachusetts, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatocellular Carcinoma (HCC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatocellular Carcinoma (HCC)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.